

General

Title

Non-Hodgkin lymphoma: percent of lymphoma patients advised to receive immunization/vaccination aligned with CDC recommendations.

Source(s)

American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p.

Measure Domain

Primary Measure Domain

Clinical Quality Measures: Process

Secondary Measure Domain

Does not apply to this measure

Brief Abstract

Description

This measure is used to assess the percent of lymphoma patients advised to receive immunization/vaccination aligned with Centers for Disease Control and Prevention (CDC) recommendations.

Rationale

Support (verbatim) from Centers for Disease Control and Prevention (CDC) guidelines:

When feasible, clinicians should administer all indicated vaccines to all persons before initiation of chemotherapy, before treatment with other immunosuppressive drugs, and before radiation or splenectomy. Persons receiving chemotherapy or radiation for leukemia and other hematopoietic malignancies, for solid tumors, or after solid organ transplant should be assumed to have altered immunocompetence (National Center for Immunization and Respiratory Diseases, 2011).

Evidence for Rationale

American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p.

National Center for Immunization and Respiratory Diseases. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ. 2011 Jan 28;60(2):1-64. [239 references] [PubMed](#)

Primary Health Components

Non-Hodgkin lymphoma (NHL); immunization; vaccination

Denominator Description

The number of lymphoma patients in your selection (see the related "Denominator Inclusions/Exclusions" field)

Numerator Description

The number of lymphoma patients in your selection

AND

Advised to receive immunization/vaccination aligned with Centers for Disease Control and Prevention (CDC) recommendations

See the related "Numerator Inclusions/Exclusions" field.

Evidence Supporting the Measure

Type of Evidence Supporting the Criterion of Quality for the Measure

A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal

Additional Information Supporting Need for the Measure

Statement from American Society of Hematology (ASH) Lymphoma Task Force on guidelines:

While recommendations from professional societies, government task forces, vaccination working groups and the Centers for Disease Control and Prevention (CDC) vary with regard to several other types of immunizations, there is unanimity concerning the usefulness of annual vaccination against influenza A and at least one vaccination against pneumococcus, which should be provided to all lymphoma patients.

Statement from ASH Lymphoma Task Force on gap:

This measure has been in use for the American Board of Internal Medicine (ABIM) Maintenance of Certification Performance Improvement Module since July 2013. Performance over the first 10 months (through May 2014) among this highly select group of hematologists is 49%. We believe performance among all hematologists would be somewhat lower. We suggest this gap remains significant.

Evidence for Additional Information Supporting Need for the Measure

American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p.

Extent of Measure Testing

The non-Hodgkin lymphoma (NHL) measure set was developed by the American Society of Hematology (ASH) using a rigorous methodology (adapted from the American Medical Association [AMA]-convened Physician Consortium for Performance Improvement [PCPI]) and has been field tested. The NHL measure set was accepted by American Board of Internal Medicine (ABIM) for use with practice improvement modules meeting Part 4 of Maintenance of Certification Requirements in 2013.

Evidence for Extent of Measure Testing

Frechette S. (Principal, Northfield Associates, LLC, Warren, VT). Personal communication. 2014 Dec 10. 1 p.

State of Use of the Measure

State of Use

Current routine use

Current Use

not defined yet

Application of the Measure in its Current Use

Measurement Setting

Ambulatory/Office-based Care

Professionals Involved in Delivery of Health Services

not defined yet

Least Aggregated Level of Services Delivery Addressed

Individual Clinicians or Public Health Professionals

Statement of Acceptable Minimum Sample Size

Unspecified

Target Population Age

Unspecified

Target Population Gender

Either male or female

National Strategy for Quality Improvement in Health Care

National Quality Strategy Aim

Better Care

National Quality Strategy Priority

Prevention and Treatment of Leading Causes of Mortality

Institute of Medicine (IOM) National Health Care Quality Report Categories

IOM Care Need

Living with Illness

IOM Domain

Effectiveness

Data Collection for the Measure

Case Finding Period

Unspecified

Denominator Sampling Frame

Patients associated with provider

Denominator (Index) Event or Characteristic

Clinical Condition

Denominator Time Window

not defined yet

Denominator Inclusions/Exclusions

Inclusions

The number of lymphoma patients in your selection

Note: Refer to the original measure documentation for a list of International Classification of Diseases, Tenth Revision (ICD-10) codes used in lymphoma patient selection.

Exclusions

Patient with prior allergic reaction to similar vaccines

Pneumococcal vaccination once in the last five years or twice five years apart

Exclusions/Exceptions

not defined yet

Numerator Inclusions/Exclusions

Inclusions

The number of lymphoma patients in your selection

AND

Advised to receive immunization/vaccination aligned with Centers for Disease Control and Prevention (CDC) recommendations

Note:

CDC recommendations for 2016 include: Annual influenza vaccination (not live vaccination) AND pneumococcal vaccination (pneumococcal conjugate vaccine [PCV13] and pneumococcal polysaccharide vaccine [PPSV23]).

This requires documentation in the patient medical record that the patient was advised to receive or was confirmed to have received recommendation for at least influenza and pneumococcal vaccination as described in the CDC guidelines.

Refer to the original measure documentation for additional vaccination information, including CDC updates for 2016.

Exclusions

Patient with prior allergic reaction to similar vaccines

Pneumococcal vaccination once in the last five years or twice five years apart

Numerator Search Strategy

Fixed time period or point in time

Data Source

Administrative clinical data

Paper medical record

Type of Health State

Does not apply to this measure

Instruments Used and/or Associated with the Measure

Unspecified

Computation of the Measure

Measure Specifies Disaggregation

Does not apply to this measure

Scoring

Rate/Proportion

Interpretation of Score

Desired value is a higher score

Allowance for Patient or Population Factors

not defined yet

Standard of Comparison

not defined yet

Identifying Information

Original Title

Measure 6: the percent of lymphoma patients recommended to receive immunization/vaccination aligned with CDC recommendations.

Measure Collection Name

Non-Hodgkin Lymphoma Measure Set

Submitter

American Society of Hematology - Medical Specialty Society

Developer

American Society of Hematology - Medical Specialty Society

Funding Source(s)

Composition of the Group that Developed the Measure

The American Society of Hematology (ASH) Lymphoma Task Force:

Joseph Connors, MD (*Co-Chair*)
Jane Winter, MD (*Co-Chair*)
Jonathan Friedberg, MD, MMSc
Mikkael Sekeres, MD, MS
Lawrence A. Solberg, Jr., MD, PhD
Karen Kayoumi (ASH)
Charles Clayton (ASH)
Suzanne Leous (ASH)
Sue Frechette, RN, MBA (Northfield Associates LLC)
Debra Reis (Healthmonix)
Lauren Patrick (Healthmonix)

Financial Disclosures/Other Potential Conflicts of Interest

Unspecified

Adaptation

This measure was not adapted from another source.

Date of Most Current Version in NQMC

2017 Feb

Measure Maintenance

American Society of Hematology (ASH) reviews/updates measures annually

Date of Next Anticipated Revision

Unspecified

Measure Status

This is the current release of the measure.

This measure updates a previous version: American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2015 Dec. 36 p.

Measure Availability

Source not available electronically.

For more information, contact the American Society of Hematology (ASH) at 2021 L Street NW, Suite 900,

NQMC Status

This NQMC summary was completed by ECRI Institute on June 19, 2015. The information was verified by the measure developer on August 27, 2015.

This NQMC summary was updated by ECRI Institute on April 18, 2016. The information was verified by the measure developer on May 24, 2016.

This NQMC summary was updated again by ECRI Institute on March 21, 2017. The information was verified by the measure developer on May 3, 2017.

Copyright Statement

This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.

For more information, contact Robert M. Plovnick, MD, MS, Director of Quality Improvement Programs at the American Society of Hematology (ASH), 2021 L Street NW, Suite 900, Washington, DC 20036.

Production

Source(s)

American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p.

Disclaimer

NQMC Disclaimer

The National Quality Measures Clearinghouse® (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the [NQMC Inclusion Criteria](#).

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.